ATE412762T1 - Vektor zur integration von heterologen sequenzen in poxvirusgenomen - Google Patents

Vektor zur integration von heterologen sequenzen in poxvirusgenomen

Info

Publication number
ATE412762T1
ATE412762T1 AT00938684T AT00938684T ATE412762T1 AT E412762 T1 ATE412762 T1 AT E412762T1 AT 00938684 T AT00938684 T AT 00938684T AT 00938684 T AT00938684 T AT 00938684T AT E412762 T1 ATE412762 T1 AT E412762T1
Authority
AT
Austria
Prior art keywords
sequences
vector
heterologuese
integration
poxvirus genomes
Prior art date
Application number
AT00938684T
Other languages
English (en)
Inventor
Stefan Wintersperger
Robert Baier
Gerd Sutter
Marion Ohlmann
Volker Erfle
Original Assignee
Helmholtz Zentrum Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen filed Critical Helmholtz Zentrum Muenchen
Application granted granted Critical
Publication of ATE412762T1 publication Critical patent/ATE412762T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00938684T 1999-05-28 2000-05-25 Vektor zur integration von heterologen sequenzen in poxvirusgenomen ATE412762T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA199900753 1999-05-28

Publications (1)

Publication Number Publication Date
ATE412762T1 true ATE412762T1 (de) 2008-11-15

Family

ID=8097154

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00938684T ATE412762T1 (de) 1999-05-28 2000-05-25 Vektor zur integration von heterologen sequenzen in poxvirusgenomen

Country Status (9)

Country Link
US (2) US6682742B1 (de)
EP (1) EP1180155B1 (de)
JP (2) JP5639736B2 (de)
AT (1) ATE412762T1 (de)
AU (1) AU5397100A (de)
CA (1) CA2372709C (de)
DE (1) DE60040662D1 (de)
DK (1) DK1180155T3 (de)
WO (1) WO2000073476A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP927599A0 (en) * 1999-03-17 1999-04-15 Curtin University Of Technology Tinnitus rehabilitation device and method
DE60040662D1 (de) * 1999-05-28 2008-12-11 Helmholtz Zentrum Muenchen Vektor zur integration von heterologen sequenzen in poxvirusgenomen
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
AU2007200016B2 (en) * 2002-05-16 2010-04-22 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of modified vaccinia virus ankara
CA2481783A1 (en) * 2002-05-16 2003-11-27 Bavarian Nordic A/S Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
PL218318B1 (pl) * 2002-05-16 2014-11-28 Bavarian Nordic As Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
AU2003293675B2 (en) * 2002-11-25 2009-04-23 Bavarian Nordic A/S Recombinant poxvirus comprising at least two cowpox ATI promoters
EP1601333B1 (de) * 2003-02-20 2013-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Neue einführungsstellen in pocken-vektoren
EP1518932A1 (de) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Mutierte Form des Modifizierten Vaccinia Virus Ankara (MVA) sowie ihre Verwendung
US7972605B2 (en) * 2006-09-08 2011-07-05 Duke University Modified vaccinia ankara virus vaccine
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364773A (en) * 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
JPH0795956B2 (ja) * 1986-09-22 1995-10-18 京都大学長 ポックスウイルス由来発現制御領域
CA1322731C (en) * 1986-09-22 1993-10-05 Hisatoshi Shida Gene for a-type inclusion body of poxvirus
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
JP2679711B2 (ja) * 1988-02-09 1997-11-19 京都大学長 ボックスウイルスのａ型封入体（ａｔｉ）遺伝子５′上流領域の改良及び当該遺伝子３′下流領域による外来遺伝子発現ベクターの改良
US5997878A (en) * 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP0951555A2 (de) * 1996-09-24 1999-10-27 Bavarian Nordic Research Institute A/S Rekombinantes mva-virus das dengue-virus antigene exprimiert und dessen verwendung in impfstoffen
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
DE60040662D1 (de) * 1999-05-28 2008-12-11 Helmholtz Zentrum Muenchen Vektor zur integration von heterologen sequenzen in poxvirusgenomen

Also Published As

Publication number Publication date
US7150874B2 (en) 2006-12-19
US20040228840A1 (en) 2004-11-18
WO2000073476A1 (en) 2000-12-07
US6682742B1 (en) 2004-01-27
DE60040662D1 (de) 2008-12-11
EP1180155A1 (de) 2002-02-20
JP2003501039A (ja) 2003-01-14
CA2372709A1 (en) 2000-12-07
CA2372709C (en) 2011-10-25
DK1180155T3 (da) 2009-02-16
JP5639736B2 (ja) 2014-12-10
AU5397100A (en) 2000-12-18
EP1180155B1 (de) 2008-10-29
JP2011234731A (ja) 2011-11-24

Similar Documents

Publication Publication Date Title
WO2005049844A3 (en) Vectors, mutant viruses and methods for generating mutant viruses
DE60040662D1 (de) Vektor zur integration von heterologen sequenzen in poxvirusgenomen
MXPA02005525A (es) Clones infecciosos.
EA200600746A1 (ru) Конструкции нуклеиновых кислот
WO2004009768A3 (en) Viral vectors containing recombination sites
AU4981101A (en) Subtilisin variants
ATE222289T1 (de) Rekombinatorische klonierung in vitro unter verwendung genmanipulierter rekombinationsorte
WO2000003030A3 (en) Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
WO2002014495A3 (en) Enhanced homologous recombination mediated by lambda recombination proteins
WO1999020766A3 (en) NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS
DK0695361T4 (da) Ekspression af heterologe gener ifølge en målekspressionsprofil
UA82998C2 (ru) Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
ATE452187T1 (de) Methode zur isolation von nukleinsäuren
EA200500879A1 (ru) Рекомбинантный поксвирус, содержащий по меньшей мере два промотора ati коровьей оспы
AR017368A1 (es) Un procedimiento para la insercion de adn foraneo en una celula hospedante, un vector recombinante utilizado en dicho procedimiento y el uso del mismo
DK1356062T3 (da) Frembringelse af rekombinanter af kunstigt gærkromosom af human cytomegalovirus
IL164179A0 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
ATE170563T1 (de) Mikroorganismen zur stabilisierung von plasmiden
WO2002081632A3 (en) Nucleic acids for transgene expression
ATE259421T1 (de) Dna-virus-vektoren und verfahren zu ihrer herstellung
WO2002079409A3 (en) Integrases for the insertion of heterologous nucleic acids into the plastid genome
DE602005027824D1 (de) Zur beschleunigung der genexpressionbei einer mässig niedrigen temperatur fähige sequenz
ATE476511T1 (de) Nukleinsäuren von hdv, deren bruchstücken und deren verwendungen
DE69839269D1 (de) Infektiöse vektoren und pflanzenklone, die sich von turnip mosaikvirus herleiten
WO2001011065A3 (en) Hepatitis a virus clones adapted for growth in agmk cells

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1180155

Country of ref document: EP